Several Indian companies are preparing to launch generic versions of GLP-1 category drug Semaglutide in India ...

Lupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement with China's Gan & Lee Pharmaceuticals. This strategic move ...

From pharma to medical insurance & digital healthcare: 2025 marks a paradigm shift: Nandita Vijayasimha, Bengaluru Tuesday, December 30, 2025, 08:00 Hrs [IST] The year 2025 marked ...

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool Biotech ...

Brand Engagement Network stock surged by 108.75%, closing at $2.50. It reached an intraday high of $2.91 and a low of $1.77, ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

That was until Eli Lilly announced it was investing $6 billion into a new pharmaceutical facility in the Limestone County portion of the city. It is the largest private investment in Alabama history, ...

Contrary to what some might think, most racehorses do have a rudimentary understanding of rhythm; it’s just at a faster pace ...

While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Professional women share what’s quietly draining their energy—and how to delegate, set boundaries, and leave emotional ...

Caregivers are the one constant in a patient’s life who are always there on their behalf — but we remain largely invisible to ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...